Highlights and Quick Summary
- EBIT Margin for the quarter ending March 31, 2022 was -1083.59% (a 59.49% increase compared to previous quarter)
- Year-over-year quarterly EBIT Margin decreased by -25.3%
- Annual EBIT Margin for 2021 was -2306.91% (a -35.28% decrease from previous year)
- Annual EBIT Margin for 2020 was -3564.38% (a 24.53% increase from previous year)
- Annual EBIT Margin for 2019 was -2862.29% (a 47.22% increase from previous year)
- Twelve month EBIT Margin ending March 31, 2022 was -1024.69% (a -16.59% decrease compared to previous quarter)
- Twelve month trailing EBIT Margin decreased by -40.71% year-over-year
Trailing EBIT Margin for the last four month:
31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
---|---|---|---|
-1024.69% | -1228.46% | -1525.21% | -1728.15% |
Visit stockrow.com/NVCN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Margin of Neovasc Inc.
Most recent EBIT Marginof NVCN including historical data for past 10 years.Interactive Chart of EBIT Margin of Neovasc Inc.
Neovasc Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | -1083.59% | – | – | – | – |
2021 | -679.42% | -963.49% | -1450.5% | -2240.43% | -2306.91% |
2020 | -1741.65% | -1623.32% | -3048.73% | -1342.86% | -3564.38% |
2019 | -1692.03% | -1397.2% | -1507.89% | -1168.88% | -2862.29% |
2018 | -1959.04% | -2008.45% | -1481.64% | -1913.18% | -1944.27% |
2017 | -994.69% | -423.7% | -482.41% | -527.66% | -1103.67% |
2016 | -243.71% | -250.03% | -759.49% | -474.11% | -387.09% |
2015 | -362.23% | -349.96% | -233.27% | -224.94% | -289.61% |
2014 | -265.85% | -116.18% | -146.83% | -10.57% | -120.18% |
2013 | -69.41% | -38.36% | -49.82% | -96.99% | -60.47% |
2012 | -40.66% | -59.31% | -92.09% | -72.51% | -62.92% |
2011 | 100.0% | – | – | – | -73.9% |
Business Profile of Neovasc Inc.
Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.